-
Taxonomy & unit
-
us-gaap: shares
-
Description
-
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
-
Summary
-
Cidara Therapeutics, Inc. quarterly/annual Weighted Average Number of Shares Outstanding, Diluted history and growth rate from Q3 2018 to Q3 2025.
- Cidara Therapeutics, Inc. Weighted Average Number of Shares Outstanding, Diluted for the quarter ending September 30, 2025 was 26.9M shares, a 312% increase year-over-year.
- Cidara Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2024 was 6.35M shares, a 45.3% increase from 2023.
- Cidara Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2023 was 4.37M shares, a 93.7% decline from 2022.
- Cidara Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2022 was 69.9M shares, a 33.2% increase from 2021.
Weighted Average Number of Shares Outstanding, Diluted, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Quarterly Growth (%)
Weighted Average Number of Shares Outstanding, Diluted, Annual (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Annual Growth (%)